DK0603305T3 - Anvendelse af et thymosin til behandling af hepatitis C - Google Patents

Anvendelse af et thymosin til behandling af hepatitis C

Info

Publication number
DK0603305T3
DK0603305T3 DK92919977.6T DK92919977T DK0603305T3 DK 0603305 T3 DK0603305 T3 DK 0603305T3 DK 92919977 T DK92919977 T DK 92919977T DK 0603305 T3 DK0603305 T3 DK 0603305T3
Authority
DK
Denmark
Prior art keywords
thymosin
treat hepatitis
immune system
potentiating
hepatitis
Prior art date
Application number
DK92919977.6T
Other languages
Danish (da)
English (en)
Inventor
Milton Mutchnick
Kenneth E Sherman
Paul Chretian
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State, Us Army filed Critical Alpha 1 Biomedicals Inc
Application granted granted Critical
Publication of DK0603305T3 publication Critical patent/DK0603305T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK92919977.6T 1991-09-13 1992-09-08 Anvendelse af et thymosin til behandling af hepatitis C DK0603305T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
DK0603305T3 true DK0603305T3 (da) 1997-09-01

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92919977.6T DK0603305T3 (da) 1991-09-13 1992-09-08 Anvendelse af et thymosin til behandling af hepatitis C

Country Status (23)

Country Link
US (3) US6001799A (fr)
EP (1) EP0603305B1 (fr)
JP (1) JP3228512B2 (fr)
KR (1) KR100254082B1 (fr)
AT (1) ATE152914T1 (fr)
AU (1) AU667327B2 (fr)
CA (1) CA2119006C (fr)
CZ (1) CZ286827B6 (fr)
DE (1) DE69219782T2 (fr)
DK (1) DK0603305T3 (fr)
ES (1) ES2103966T3 (fr)
FI (1) FI107879B (fr)
GR (1) GR3024025T3 (fr)
HK (1) HK1021687A1 (fr)
HU (1) HU221006B1 (fr)
MX (1) MX9205240A (fr)
NO (1) NO941310D0 (fr)
RO (1) RO111991B1 (fr)
RU (1) RU2104010C1 (fr)
SG (1) SG64897A1 (fr)
TW (1) TW224053B (fr)
WO (1) WO1993005806A1 (fr)
ZA (1) ZA926964B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (fr) * 1991-09-13 1994-05-21 Paul B Chretien
EP0728010A4 (fr) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals Methode de traitement de porteurs de l'hepatite b presentant un etat pathologique minime
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
WO1994001125A1 (fr) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition et procede de traitement de l'hepatite b
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (fr) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
PT731710E (pt) * 1993-11-05 2003-09-30 Sciclone Pharmaceuticals Inc Composicoes contendo timosine alpha 1 destinadas ao tratamento de pacientes sofrendo duma doenca de figado descompensado
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
EP0886527B1 (fr) * 1996-02-28 2001-09-12 Unihart Corporation Compositions pharmaceutiques comportant de l'interferon alpha humain naturel
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
ES2275711T3 (es) * 2000-08-07 2007-06-16 Sciclone Pharmaceuticals, Inc. Tratamiento de la hepatitis c con timosina, interferon y ribavirina.
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002044717A1 (fr) * 2000-12-01 2002-06-06 Cornell Research Foundation Modele animal d'infection par virus des flaviviridae
WO2003026589A2 (fr) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
IL161022A0 (en) * 2001-10-05 2004-08-31 Intermune Inc Methods of treating liver fibrosis and hepatitis c virus infection
KR100902197B1 (ko) * 2001-10-26 2009-06-11 로드아일랜드하스피틀 티모신에 의한 유전적 면역화 증대
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
JP2005522443A (ja) * 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US8207294B2 (en) 2003-03-28 2012-06-26 Sciclone Pharmaceuticals, Inc. Treatment of Aspergillus infections with alpha thymosin peptides
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
WO2005009418A2 (fr) * 2003-07-25 2005-02-03 Idenix (Cayman) Limited Analogues des nucleosides puriques pour traiter flaviviridae et notamment l'hepatite c
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (fr) 2004-05-05 2005-11-17 Yale University Nouveaux analogues antiviraux de l'helioxanthine
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (fr) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation de ribofuranosyle pyrimidines et purines a substitution 2'-fluoro-2'- alkyl- ou eventuellement a autre substitution ainsi que derives de celles-ci
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
CA2634749C (fr) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies
EP1832295A1 (fr) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Utilisation de PTX3 pour le traitement de maladies virales
WO2007128647A1 (fr) * 2006-05-02 2007-11-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. UTILISATION DE LA THYMOSINE α1, SEULE OU EN COMBINAISON AVEC LA PTX3 OU LE GANCICLOVIR, POUR LE TRAITEMENT DE L'INFECTION À CYTOMEGALOVIRUS
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (fr) * 2008-10-08 2012-07-04 Univ Miami Régulation de lymphocytes et utilisations associées
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (fr) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
NO941310L (no) 1994-04-12
MX9205240A (es) 1993-07-01
ZA926964B (en) 1993-04-26
CZ286827B6 (cs) 2000-07-12
FI941133A0 (fi) 1994-03-10
US6001799A (en) 1999-12-14
HU221006B1 (hu) 2002-07-29
NO941310D0 (no) 1994-04-12
TW224053B (fr) 1994-05-21
AU2644792A (en) 1993-04-27
ATE152914T1 (de) 1997-05-15
RO111991B1 (ro) 1997-04-30
CZ55194A3 (en) 1994-10-19
GR3024025T3 (en) 1997-10-31
JPH06510998A (ja) 1994-12-08
RU94022480A (ru) 1996-07-20
KR100254082B1 (ko) 2000-09-01
HU9400758D0 (en) 1994-06-28
HUT75166A (en) 1997-04-28
WO1993005806A1 (fr) 1993-04-01
RU2104010C1 (ru) 1998-02-10
EP0603305A1 (fr) 1994-06-29
JP3228512B2 (ja) 2001-11-12
DE69219782T2 (de) 1997-10-09
DE69219782D1 (de) 1997-06-19
CA2119006C (fr) 2005-08-23
ES2103966T3 (es) 1997-10-01
US20070218033A1 (en) 2007-09-20
FI107879B (fi) 2001-10-31
US5849696A (en) 1998-12-15
AU667327B2 (en) 1996-03-21
SG64897A1 (en) 1999-05-25
FI941133A (fi) 1994-03-10
EP0603305B1 (fr) 1997-05-14
CA2119006A1 (fr) 1993-04-01
HK1021687A1 (en) 2000-06-23

Similar Documents

Publication Publication Date Title
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
DE69103844D1 (de) Einstufiger Venenkatheter.
DE69232565D1 (de) Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
HUP9900929A2 (hu) Hepatitisz C-ben szenvedő betegek ismételt kezelési eljárásai konszenzus interferonnal
DE3667895D1 (de) Einrichtung zur erzeugung eines im wesentlichen homogenen plasmas.
ATE196849T1 (de) Verfahren zur behandlung von multiplesklerose
DK447489A (da) Metode til stabilisering af blod
DK0648120T3 (da) Anvendelse af phosphonater til behandling af osteoporose
DK81691A (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
PH31116A (en) Methods for the treatment of infection caused by hepatitis B virus (hbv).
ATE155345T1 (de) Gegengift immunsera
DK0588873T3 (da) Behandling af levercancer
DK0687181T3 (da) Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling
NO894187D0 (no) Terapeutiske forbindelser.
DK0517787T3 (da) Fremgangsmåde til behandling af terapiresistent skizofreni med amperozide
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
DK0589348T4 (da) Fremgangsmåde til immunkemisk kvantificering af inaktiverede antigener
DK376386A (da) Anvendelse af immunglobuliner
DK27391D0 (da) Metode til oeget opbygget insulineffekt
DK38491D0 (da) Method for increased builded effect of insulin
DE68902143D1 (de) Mund-zu-mund-beatmungsmaske.
ATE78181T1 (de) Mund-zu-mund-beatmungsmaske.
ES1007997Y (es) Aspirador perfeccionado de fondos de piscinas.
ITVR910084A1 (it) Pedana emoflebodinamica antistasi